Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Intervacc AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:IVACC vs VRTX, REGN, MRNA: Days Payable Comparison
For the Biotechnology subindustry, Intervacc AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intervacc AB Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intervacc AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Intervacc AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Intervacc AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intervacc AB (OSTO:IVACC) has a Days Payable of 0.00 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Intervacc AB and its competitors. Over the past decade, Intervacc AB's Days Payable has ranged from 53.80 to 19,155.84. According to the industry distribution chart, Intervacc AB ranks #425 out of 709 companies in the Biotechnology industry, placing it in the top 59.9%.
Is Intervacc AB's Days Payable too high?
Intervacc AB's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 53.80 to a high of 19,155.84. Based on the distribution chart, Intervacc AB ranks #425 out of 709 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Intervacc AB has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Intervacc AB's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intervacc AB ranks #425 out of 709 companies for Days Payable. This places Intervacc AB in the lower half of its industry. The industry median Days Payable is 111.24. Historically, Intervacc AB's own Days Payable has ranged from 53.80 to 19,155.84 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.24, based on 709 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Intervacc AB and its competitors. For the Biotechnology industry, the median Days Payable is 111.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intervacc AB's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intervacc AB stock overvalued right now?
Based on GuruFocus' analysis, Intervacc AB (OSTO:IVACC) is currently considered Fairly Valued. The stock's GF Value™ is kr1.06, compared to a current price of kr1.11 — trading 4.7% above its estimated fair value. The current Days Payable is 0.00. Intervacc AB's overall GF Score™ is 62/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Intervacc AB (OSTO:IVACC), the current Days Payable is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intervacc AB (OSTO:IVACC) Overvalued in 2026?
Based on GuruFocus' analysis, Intervacc AB stock appears to be overvalued.
The current stock price of kr1.11 is trading 4.7% above its estimated GF Value™ of kr1.06.
GuruFocus considers Intervacc AB to be Fairly Valued.
Key valuation signals for OSTO:IVACC:
Days Payable: 0.00
GF Value™: kr1.06 vs. price of kr1.11 (4.7% above fair value)
No single metric tells the full story. See the OSTO:IVACC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
62GF Score
Get the complete analysis for OSTO:IVACC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IVACC has been successfully added to your 
